Related Experiment Videos
Current status of adoptive immunotherapy of cancer
Abstract:
The sentinel observations made by William B. Coley. M.D. in the 1890s that patients with malignancics can respond to the intratumoral inoculation of live bacterial organisms or bacterial toxins became the cornerstone for the development of immunotherapy for cancers. It has been repeatedly demonstrated that tumors express unique proteins which can trigger an immune response. The adoptive transfer of immune cells to the host with established malignancy can mediate complete eradication of local or disseminated tumors and result in systemic immunity. This review summarizes the current experimental as well as clinical status of adoptive immunotherapy of cancer. There are a number of different methods to isolate tumor-reactive T cells from the tumor-bearing host and allow for their ex vivo expansion. A new direction in this field includes attempts to up-regulate the immunogenicity of tumors by genetically modifying tumor cells to express immunoregulatory peptides (i.e. cytokines, co-stimulatory molecules, etc.) in order to exploit endogenously weak immune responses to autochthonous tumors. Other new directions involve developing methods to generate or isolate tumor-reactive T cells subsets by selective in vitro stimulation (i.e. bacterial superantigens) or genetic engineering of activated T cells to enhance their ability to mediate tumor destruction. Although adoptive immunotherapy has thus far added little to the routine treatment of human cancer, it is likely that continued efforts at defining the elements involved in T cell recognition and destruction of tumor cells will broaden the applicability of T cells as important therapeutic reagents.
Insights
Adoptive immunotherapy harnesses the immune system to fight cancer by transferring tumor-specific immune cells. This approach, rooted in early observations of cancer patient responses to bacteria, shows promise for future cancer treatments.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Early 1890s observations by William B. Coley demonstrated cancer patient responses to bacterial inoculations, laying groundwork for cancer immunotherapy.
- Tumors express unique proteins that can elicit an immune response, a key principle in developing cancer immunotherapies.
- Adoptive transfer of immune cells can eradicate established tumors and induce systemic immunity in hosts with malignancy.
Purpose of the Study:
- To review the current experimental and clinical status of adoptive immunotherapy for cancer.
- To explore novel strategies for enhancing tumor immunogenicity and T cell-mediated tumor destruction.
Main Methods:
- Isolation and ex vivo expansion of tumor-reactive T cells from tumor-bearing hosts.
- Genetic modification of tumor cells to express immunoregulatory peptides (cytokines, co-stimulatory molecules) to enhance immunogenicity.
- Development of methods for selective in vitro stimulation (e.g., bacterial superantigens) or genetic engineering of T cells to improve tumor-killing capabilities.
Main Results:
- Multiple methods exist for isolating and expanding tumor-reactive T cells for adoptive transfer.
- Strategies are emerging to increase tumor immunogenicity and enhance T cell-mediated cancer destruction.
- While not yet routine, adoptive immunotherapy research continues to define T cell roles in cancer therapy.
Conclusions:
- Adoptive immunotherapy holds significant potential for cancer treatment by leveraging the host's immune system.
- Continued research into T cell recognition and destruction mechanisms will expand its therapeutic applications.
- Future efforts may broaden the use of T cells as critical therapeutic agents in human cancer treatment.